|Videos|August 26, 2021
Role of Second Generation FLT3 Inhibitors in AML
Expert examines the status of second-generation FLT3 inhibitors in newly diagnosed AML patients and the challenge with comparing clinical trial efficacy endpoints.
Advertisement
Episodes in this series
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Related Content
Advertisement
Advertisement
Trending on Pharmacy Times
1
Interview with Sa'ed al-Olimat, PharmD: How Pharmacists are Shaping the Future of Psychedelic Therapy
2
December 2025 Product Updates
3
A Healthy Gut Could Improve Mental Health
4
Reimagining Pharmacy: A Call to Action for Pharmacy Professionals
5